Background/Aim: There is a strong evidence for the involvement of genetic factors in diabetic microvascular complications. The aim of our study was to investigate the role of molecular variants of the TGF-β1 (transforming growth factor beta 1) and the TSC-22 (transforming growth factor beta stimulated clone 22) genes in diabetic nephropathy and diabetic retinopathy in type 2 diabetes. Methods: A case-control study was conducted in 503 patients and 400 healthy subjects. DNA samples were genotyped by polymerase chain reaction and restriction fragment length polymorphism methods. Results: Among the patients, 245 had diabetic nephropathy, 195 had retinopathy, and 168 were free from complications. All subjects were genotyped for T869C and C –509T polymorphisms of the TGF-β1 gene and for –396 polymorphism of the TSC-22 gene. A significantly increased frequency of the CC genotype of the T869C polymorphism was observed in patients with nephropathy and retinopathy (33 and 48%, respectively, vs. 19 and 15%, respectively, in controls and patients free from complications). The frequency of the C allele was also higher (0.58 for nephropathy and 0.64 for retinopathy vs. 0.42 in controls). The G allele of the TSC-22 polymorphism was associated with an increased risk of diabetic nephropathy (frequency 0.15 vs. 0.07 and 0.06, respectively, in patients free from complications and controls). An interaction was observed between the G allele of the TSC-22 polymorphism and the C-allele of the TGF-β polymorphism. Conclusions: Our data suggest the association of TGF-β T869C gene polymorphism with an increased risk of nephropathy and retinopathy in type 2 diabetes patients. It interacts with the TSC-22 gene involved in the TGF-β signaling pathway, promoting the development of diabetic nephropathy.
Lipids profile and some anthropometric measurements in diabetic and non-diabetic peritoneal dialysis patientsIn chronic renal failure some lipid disturbances are observed even in early stage of the disease (2,4,5,9). They are characterized mainly by elevated plasma levels of total cholesterol and triglycerides (1, 5). The other disturbance which occurs in renal failure is an abnormal level of apolipoprotein (3). The intensification of described plasma lipids disturbances is raising with the progress of the disease. Renal dyslipidemia was first described in hemodialyzed patients (1), but some abnormalities in lipid profile are observed in peritoneal dialyzed patients as well (4, 9). Dialysis can moderately attenuate dyslipidemia, but its character remains unchanged.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.